Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Stergios A. Pοlyzos, Dimitrios G. Goulis, Όλγα Γιουλεμέ, et al.
Current Obesity Reports (2022) Vol. 11, Iss. 3, pp. 166-179
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Simon Kloock, Christian G. Ziegler, Ulrich Dischinger
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108549-108549
Open Access | Times Cited: 51
Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy
Stergios A. Pοlyzos, Lampros Chrysavgis, Ilias D. Vachliotis, et al.
Seminars in Cancer Biology (2023) Vol. 93, pp. 20-35
Closed Access | Times Cited: 48
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 48-58
Open Access | Times Cited: 29
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease
Stergios A. Pοlyzos, Ilias D. Vachliotis, Christos S. Mantzoros
Metabolism (2023) Vol. 147, pp. 155676-155676
Closed Access | Times Cited: 36
Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023
Harold Bays, Shagun Bindlish, Tiffany Lowe Clayton
Obesity Pillars (2023) Vol. 5, pp. 100056-100056
Open Access | Times Cited: 32
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management
Stergios A. Pοlyzos, Christos S. Mantzoros
Metabolism (2024) Vol. 157, pp. 155936-155936
Closed Access | Times Cited: 10
How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4651-4651
Open Access | Times Cited: 30
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
K.F. Au, Ming‐Hua Zheng, Wei‐Jei Lee, et al.
Current Obesity Reports (2024) Vol. 13, Iss. 4, pp. 818-830
Closed Access | Times Cited: 7
The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Pharmacological Research (2022) Vol. 181, pp. 106261-106261
Closed Access | Times Cited: 25
Pharmacological Treatments and Natural Biocompounds in Weight Management
Amin Gasmi, Pavan Kumar Mujawdiya, Amine Nehaoua, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 212-212
Open Access | Times Cited: 12
Prevalence of Non-alcoholic Fatty Liver Disease in Iran: A Systematic Review and Meta-analysis
Seidamir Pasha Tabaeian, Aziz Rezapour, Samad Azari, et al.
Journal of Clinical and Experimental Hepatology (2023) Vol. 14, Iss. 1, pp. 101209-101209
Closed Access | Times Cited: 12
Lipid-Lowering and Antioxidant Effects of Self-Assembled Astaxanthin–Anthocyanin Nanoparticles on High-Fat Caenorhabditis elegans
Deyang Yu, Meng Guo, Mingqian Tan, et al.
Foods (2024) Vol. 13, Iss. 4, pp. 514-514
Open Access | Times Cited: 4
GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis
Yu Yao, Qi Wang, Xi Huang, et al.
International Journal of Biological Macromolecules (2024) Vol. 278, pp. 134779-134779
Closed Access | Times Cited: 3
Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma
Ilias D. Vachliotis, Ioannis Valsamidis, Stergios A. Pοlyzos
Cancers (2023) Vol. 15, Iss. 21, pp. 5306-5306
Open Access | Times Cited: 5
Linalool Mitigated High-Fat Diet–Induced Non-alcoholic Fatty Liver Disease by Regulating the Intestinal-Hepatic Axis via TGF-β/NF-kB/TLR4/ZO-1 Pathway
Tamilmani Periyasamy, V. V. Sathibabu Uddandrao, P. Chandrasekaran, et al.
Revista Brasileira de Farmacognosia (2023) Vol. 33, Iss. 3, pp. 617-628
Closed Access | Times Cited: 4
Pharmacological effects of mTORC1/C2 inhibitor in a preclinical model of NASH progression
Mahak Arora, Zuzana Pavlíková, Tomáš Kučera, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115447-115447
Open Access | Times Cited: 4
Challenges in Obstructive Sleep Apnea Management in Elderly Patients
Aude Joskin, Marie Bruyneel
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7718-7718
Open Access | Times Cited: 1
Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD)
Adnan Khan, Heather M. Ross, Natalia Salinas Parra, et al.
Livers (2022) Vol. 2, Iss. 4, pp. 264-282
Open Access | Times Cited: 7
Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?
Marzia Friuli, C. Sepe, Elisabetta Panza, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Liver at crossroads: unraveling the links between obesity, chronic liver diseases, and the mysterious obesity paradox
Maha Elsabaawy
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Chara Tsiampali, Paraskevi Papaioannidou, Antonis Goulas, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1063-1072
Closed Access | Times Cited: 3
Is adiponectin deficiency a critical factor for sevoflurane induced neurocognitive dysfunction?
Jiaqi Wang, Raymond Chuen‐Chung Chang, John Man Tak Chu, et al.
Medical Hypotheses (2023) Vol. 182, pp. 111241-111241
Open Access | Times Cited: 2
Understanding Primary Care Physician Perspectives on the Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: A Qualitative Study
Natalia I. Heredia, Jemima C. John, Sonia Singh, et al.
INQUIRY The Journal of Health Care Organization Provision and Financing (2024) Vol. 61
Open Access
Outdoor environment and obesity: A review of current evidence
Evangelia A Polyzou, Stergios A. Pοlyzos
Metabolism Open (2024) Vol. 24, pp. 100331-100331
Open Access
Page 1 - Next Page

Scroll to top